Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in
 Carotid Artery Stenting
Inclusion Criteria:

 1. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the
 degree of stenosis should more than 50% (Based on NASCET Criteria), in asymptomatic
 patients the degree of stenosis should more than 70% (Based on NASCET Criteria);

 2. Tolerance to any of the study medications, including TZ, clopidogrel, aspirin and
 statins;

 3. Hypertensive patients with or without oral antihypertensive drugs

 4. Can cooperate with and complete brain MRI examination;

 5. Stable vital signs, cardiopulmonary, liver and kidney function was no obvious
 abnormalities;

 6. Has a negative pregnancy test within 7 days before randomization and no childbearing
 potential;

 7. Stable vital sign, normal renal and hepatic functions;

 8. Informed consent.

 Exclusion Criteria:

 1. Evolving stroke;

 2. Hemorrhagic tendency；

 3. Severe dementia or Prior major ipsilateral stroke, if likely to confound study
 endpoints;

 4. Chronic atrial fibrillation or any other Cardiogenic emboli source disease;

 5. Myocardial infarction within previous 30 days;

 6. Spontaneous Intracerebral Hemorrhage within the past 180 days, Hemorrhagic conversion
 of an ischemic stroke within the past 60 days or recent (<7 days) large area cerebral
 infarction has a hemorrhagic conversion tendence;

 7. Any conditions that hampers proper angiographic assessment or makes percutaneous
 arterial access unsafe;

 8. High risk candidates of CAS defined as the Carotid Revascularization Endarterectomy
 vs. Stenting Trial (CREST);

 9. Thiazides taken within 14 days before randomization;

 10. Participating in any other clinical trial that has not completed the required protocol
 follow-up period;